Enanta Pharmaceuticals (ENTA) Competitors $8.40 -0.29 (-3.34%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.40 0.00 (0.00%) As of 08/29/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ENTA vs. DNA, DAWN, PROK, TBPH, IMTX, ABUS, GHRS, KALV, KURA, and SIGAShould you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Ginkgo Bioworks (DNA), Day One Biopharmaceuticals (DAWN), ProKidney (PROK), Theravance Biopharma (TBPH), Immatics (IMTX), Arbutus Biopharma (ABUS), GH Research (GHRS), KalVista Pharmaceuticals (KALV), Kura Oncology (KURA), and Siga Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry. Enanta Pharmaceuticals vs. Its Competitors Ginkgo Bioworks Day One Biopharmaceuticals ProKidney Theravance Biopharma Immatics Arbutus Biopharma GH Research KalVista Pharmaceuticals Kura Oncology Siga Technologies Ginkgo Bioworks (NYSE:DNA) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk. Which has more risk & volatility, DNA or ENTA? Ginkgo Bioworks has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Which has higher valuation & earnings, DNA or ENTA? Enanta Pharmaceuticals has lower revenue, but higher earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGinkgo Bioworks$227.04M3.31-$547.03M-$5.86-2.17Enanta Pharmaceuticals$67.64M2.66-$116.04M-$4.32-1.94 Does the media favor DNA or ENTA? In the previous week, Ginkgo Bioworks had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 4 mentions for Ginkgo Bioworks and 2 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.77 beat Ginkgo Bioworks' score of 0.68 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enanta Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is DNA or ENTA more profitable? Ginkgo Bioworks has a net margin of -136.56% compared to Enanta Pharmaceuticals' net margin of -141.98%. Ginkgo Bioworks' return on equity of -43.25% beat Enanta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks-136.56% -43.25% -22.29% Enanta Pharmaceuticals -141.98%-89.02%-27.28% Do insiders and institutionals have more ownership in DNA or ENTA? 78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 9.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 13.9% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend DNA or ENTA? Ginkgo Bioworks presently has a consensus target price of $9.50, indicating a potential downside of 25.26%. Enanta Pharmaceuticals has a consensus target price of $21.67, indicating a potential upside of 157.94%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ginkgo Bioworks 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Enanta Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEnanta Pharmaceuticals beats Ginkgo Bioworks on 9 of the 16 factors compared between the two stocks. Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTA vs. The Competition Export to ExcelMetricEnanta PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$185.77M$2.49B$5.66B$9.84BDividend YieldN/A1.67%3.93%4.04%P/E Ratio-1.9422.8083.2726.61Price / Sales2.66509.21451.26176.28Price / CashN/A177.7737.7059.65Price / Book2.265.9810.556.59Net Income-$116.04M$32.94M$3.27B$266.12M7 Day Performance-4.87%-1.28%0.42%0.16%1 Month Performance10.38%3.54%5.91%3.02%1 Year Performance-34.78%-3.68%48.11%19.65% Enanta Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTAEnanta Pharmaceuticals3.7834 of 5 stars$8.40-3.3%$21.67+157.9%-35.5%$185.77M$67.64M-1.94160Positive NewsDNAGinkgo Bioworks1.0499 of 5 stars$12.06-3.9%$9.50-21.2%+79.5%$742.96M$227.04M-2.06640Analyst UpgradeDAWNDay One Biopharmaceuticals2.5333 of 5 stars$6.97-3.2%$25.29+262.8%-45.1%$737.51M$131.16M-7.3460News CoveragePositive NewsPROKProKidney3.5803 of 5 stars$2.35-2.5%$6.25+166.0%-0.8%$709.22M$80K-4.123TBPHTheravance Biopharma2.8445 of 5 stars$13.80-0.8%$21.33+54.6%+69.1%$700.53M$64.38M57.50110News CoverageIMTXImmatics2.3901 of 5 stars$5.23-8.1%$14.67+180.4%-54.1%$691.62M$168.65M-8.05260ABUSArbutus Biopharma2.4877 of 5 stars$3.50-2.5%$5.50+57.1%-3.1%$688.20M$6.17M-12.0790Positive NewsGHRSGH Research2.2722 of 5 stars$13.18+0.8%$32.00+142.8%+23.1%$680.53MN/A-17.8110News CoverageUpcoming EarningsKALVKalVista Pharmaceuticals3.6564 of 5 stars$12.99-3.1%$26.29+102.4%+3.5%$675.06MN/A-3.52100News CoveragePositive NewsUpcoming EarningsKURAKura Oncology3.9321 of 5 stars$7.65flat$24.10+215.0%-61.5%$664M$53.88M-3.38130News CoveragePositive NewsSIGASiga Technologies2.4959 of 5 stars$8.70-4.7%N/A-8.6%$653.76M$138.72M7.7040 Related Companies and Tools Related Companies DNA Competitors DAWN Competitors PROK Competitors TBPH Competitors IMTX Competitors ABUS Competitors GHRS Competitors KALV Competitors KURA Competitors SIGA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTA) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
